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We have applied the soluble pyridine nucleotide transhydrogenase of Pseudomonas fluorescens to a cell-free
system for the regeneration of the nicotinamide cofactors NAD and NADP in the biological production of the
important semisynthetic opiate drug hydromorphone. The original recombinant whole-cell system suffered from
cofactor depletion resulting from the action of an NADP1-dependent morphine dehydrogenase and an NADH-
dependent morphinone reductase. By applying a soluble pyridine nucleotide transhydrogenase, which can trans-
fer reducing equivalents between NAD and NADP, we demonstrate with a cell-free system that efficient cofactor
cycling in the presence of catalytic amounts of cofactors occurs, resulting in high yields of hydromorphone. The
ratio of morphine dehydrogenase, morphinone reductase, and soluble pyridine nucleotide transhydrogenase is
critical for diminishing the production of the unwanted by-product dihydromorphine and for optimum hydro-
morphone yields. Application of the soluble pyridine nucleotide transhydrogenase to the whole-cell system resulted
in an improved biocatalyst with an extended lifetime. These results demonstrate the usefulness of the soluble py-
ridine nucleotide transhydrogenase and its wider application as a tool in metabolic engineering and biocatalysis.
The pyridine nucleotide cofactors NAD and NADP are es-
sential components of the cell, where they act as electron car-
riers in reduction and oxidation reactions. A large percentage
of enzymes are dependent on these coenzymes for their activ-
ities (SwissProt database, http://www.expasy.ch/sprot/), and the
cofactors are known to be involved in a vast amount of reac-
tions (EcoCyc database). Many of the NAD(P)-dependent oxi-
doreductases catalyze reactions of commercial interest and
have many applications, for instance, in the production of chi-
ral compounds, amino acids, steroids, and other therapeutics
for the pharmaceutical industry, in the modification or synthe-
sis of polymers, in the oxidative remediation of pollutants, in
the oxyfunctionalization of hydrocarbons, and in the construc-
tion of biosensors (14, 18). The high cost of the pyridine nu-
cleotide cofactors which need to be provided in stoichiometric
quantities in enzyme reactions is an important commercial
issue. Cofactor regeneration is, therefore, an important con-
sideration when processes involving NAD(P)-dependent oxi-
doreductases are to be applied in a commercial setting.
In cell-free systems the cofactors must be supplied, albeit at
a lower-than-stoichiometric concentration (catalytic amounts),
when cofactor regeneration is achieved. Alternatively, pro-
cesses dependent on these cofactors can be carried out in
whole cells which are known to have some reserves of the co-
factor, but also here cofactor depletion can be a problem.
Mostly NAD is regenerated using formate dehydrogenase,
while NADP is recycled using glucose dehydrogenase. Re-
cently, Galkin et al. described the synthesis of optically active
amino acids from 2-keto acids using recombinant Escherichia
coli coexpressing an amino acid dehydrogenase and a formate
dehydrogenase for recycling NAD (10), and NADP recycling
by recombinant E. coli expressing glucose dehydrogenase has
similarly been described (17), although in both cell-free and
whole-cell systems the supply of extra substrate, respectively,
formate and glucose, is necessary.
The biological production of the potent analgesic hydromor-
phone is an example of a biotransformation process that suffers
problems of cofactor depletion. The whole-cell recombination
process is mediated by two constitutively expressed Pseudomo-
nas enzymes, an NADP1-dependent morphine dehydrogenase
(MDH) and an NADH-dependent morphinone reductase
(MR) (5, 6, 8, 12) (Fig. 1). Although this biotransformation
system was promising in that it was the first to demonstrate the
biological production of hydromorphone, some problems were
identified (Fig. 1). The unwanted by-product dihydromorphine
accumulated; this by-product, together with the depletion of
cofactors, the poor solubility of the opiate substrate, and the
instability of the intermediate morphinone (22), allowed only a
limited amount of material to be transformed to hydromor-
phone and thereby decreased the lifetime and usefulness
of the system. It was envisaged that hydromorphone yields
could be improved by increasing the ratio of MR to MDH and
by enhancing the transfer of reducing equivalents from NADPH,
produced in the MDH reaction, to NADH, needed for the
irreversible MR reaction.
Here we address the problems of cofactor depletion in the
biological production of hydromorphone by using the soluble
pyridine nucleotide transhydrogenase (STH) of Pseudomonas
fluorescens (7), an enzyme which can catalyze the transfer
of reducing equivalents according to the following equation:
NAD1 1 NADPH º NADH 1 NADP1. We show that effi-
cient cofactor cycling (Fig. 2) can be achieved using this en-
zyme and that a reuseable whole-cell biocatalyst is produced.
The results demonstrate the usefulness of STH as a tool in
biocatalysis and metabolic engineering.
* Corresponding author. Mailing address: Institute of Biotechnol-
ogy, University of Cambridge, Tennis Court Rd., Cambridge CB2
1QT, United Kingdom. Phone: 44 1223 334168. Fax: 44 1223 334162.
E-mail: n.bruce@biotech.cam.ac.uk.
† Present address: Institute of Cell and Molecular Biology, Univer-
sity of Edinburgh, Edinburgh EH9 3JR, United Kingdom.
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MATERIALS AND METHODS
Chemicals and other materials. NADH, NADPH, NAD1, NADP1, and thio-
nicotinamide NAD1 were obtained from Sigma (Poole, Dorset, United King-
dom). Restriction enzymes were purchased from New England Biolabs Ltd.
(Hitchin, United Kingdom). Morphine alkaloids were kindly donated by Mac-
farlan Smith Ltd. (Edinburgh, United Kingdom). Other reagents were of ana-
lytical or higher grade. MDH, MR, and STH were purified from recombinant E.
coli as described previously (5, 7, 8). The specific activities of the enzyme prep-
arations employed were 11 U of MDH per mg, 6 U of MR per mg, and 276 U
of STH per mg.
Expression constructs. The original pBluescript SK1-derived expression con-
struct pMORAB5 containing both morA (which encodes MDH) and morB
(which encodes MR) with their respective constitutive Pseudomonas promoters
(9) was employed for the whole-cell biotransformations. The P. fluorescens sth
gene was introduced into E. coli on a compatible plasmid, ps 1EMBL (21). The
sth gene was excised from pSTH1 (7) as a 1.5-kb PstI-SalI fragment and sub-
cloned into the PstI-XhoI sites of the low-copy-number plasmid ps 1EMBL, and
the resulting plasmid was denoted pPFSTH4.
A second construct was made where the morA gene was replaced by morA
C80S z K244M (25), which encodes a less active and more stable MDH. A 1.2-kb
PstI fragment bearing the mutant morA gene complete with its upstream ribo-
some binding site and promoter sequences was excised from pMDH1.7 (25)
and ligated into PstI-digested ps 1EMBL (21). This resulted in the construct
pMORA4C80S z K244M, which contained suitable restriction sites for further
subcloning. Transformants were selected by growth on Luria-Bertani agar con-
taining kanamycin at 50 mg/ml, 5-bromo-4-chloro-3-indoyl-b-D-galactoside at 32
mg/ml and 0.5 mM isopropyl-b-D-thiogalactopyranoside. Plasmid DNA was pre-
pared from white insert-containing colonies and analyzed by digestion with MslI
and PstI to determine the orientation of the insert. A 1.2-kb HindIII/EcoRI
fragment carrying the mutant morA gene, ribosome binding site, and promoter
region was excised from pMORA4K244M z C80S and ligated into HindIII- and
EcoRI-digested pMORB3 (9), which carried a single copy of morB, together with
its ribosome binding site and promoter region, creating the construct pMORB3-
AC80S z K244M.
Strains and culture conditions. E. coli JM109 was used as the host organism
for all cloning transformations and whole-cell biotransformations. Plasmids were
introduced into E. coli JM109 using the method of Hanahan (13). In cases where
cells were to contain pPFSTH4 in addition to other plasmids, E. coli JM109 was
transformed sequentially with the individual plasmids. Transformants were main-
tained on Luria-Bertani agar plates (23). Cells were routinely grown in SOB
medium (23) at 37°C on a rotating shaker with the addition of ampicillin or
carbenicillin at 100 mg/ml and/or kanamycin at 50 mg/ml to select for the pres-
ence of plasmids when appropriate. When cells were to be used for biotransfor-
mation purposes, a small culture, grown for approximately 16 h as described
above, was used as a 5 to 10% (vol/vol) inoculum in 500 ml of fresh medium with
antibiotics, which was then grown to stationary phase at 37°C over approximately
16 h.
Cell-free biotransformations. Cell-free transformations were performed at
30°C in a solution containing 50 mM Tris-HCl (pH 8.0), 1 mM dithiothreitol, 20
mM morphine, and purified preparations of MDH, MR, and STH in a total
volume of 200 ml. Transformations were performed in the presence of catalytic
amounts of cofactors, either with NADPH and NAD1, both at a concentration
of 0.2 mM, or with the four cofactors at the following concentrations: 2 mM
NAD1, 0.15 mM NADH, 0.25 mM NADP1, and 0.2 mM NADPH. Samples (30
ml) were taken at regular intervals, and proteins were removed by precipitation
with glacial acetic acid and centrifugation prior to high-performance liquid chro-
matography (HPLC) analysis.
Whole-cell incubations. Cells grown as indicated above were harvested by
centrifugation at 17,310 3 g for 15 min at 4°C. Cells were then washed with 50
mM Tris-HCl (pH 8.0) and recentrifuged. The supernatant was removed, and the
pelleted cells were used immediately or stored on ice for a few hours prior to use
in biotransformations. Small-scale whole-cell biotransformations (3-ml total vol-
ume) were carried out using recombinant E. coli JM109 at a final cell density of
0.17 g (wet weight) per ml with 20 mM morphine in 50 mM Tris-HCl (pH 8.0).
Biotransformations were carried out at 30°C on a rotary shaker, and samples
(100 to 200 ml) were taken at regular intervals. Samples were clarified by cen-
trifugation and analyzed for opiate content by HPLC.
Chromatography of alkaloids. Samples were analyzed for opiate content by
reverse-phase HPLC using a 5-mm (inside diameter) C18 Spherisorb column on
a Waters Corporation (Milford, Mass.) model 2690 separation module with a
Waters model 996 photodiode array detector. The mobile phase consisted of
20% (vol/vol) acetonitrile and 80% (vol/vol) 15 mM phosphate buffer (pH 3.5)
(prepared by adjusting the pH of 15 mM KH2PO4 to 3.5 with H3PO4). A flow
rate of 1 ml/min was used, and alkaloids were detected by absorbance at 230 nm.
The method was essentially as described by French et al. (9) but without prior
extraction, and analysis was performed using Millennium software (Waters Cor-
poration).
MDH and MR assays. Cell extracts of recombinant E. coli JM109 were pre-
pared by French pressing cell suspensions with a density of 0.5 g (wet weight) per
ml in 50 mM Tris-HCl (pH 8.0) at 2,500 lb/in2, followed by centrifugation at
31,180 3 g 4°C for 1 h. Extracts were analyzed for MDH and MR activities using
previously described assays (5, 8). One unit of MDH activity is the amount of
enzyme necessary to reduce 1 mmol of NADP1 in 1 min at 30°C using morphine
as the substrate, and 1 U of MR is the amount of enzyme required to oxidize 1
mmol of NADH in 1 min at 30°C using codeinone as the substrate. STH activity
FIG. 1. Transformation of morphine by MDH and MR from P. putida
M10.
FIG. 2. Cofactor cycling by STH in the biological production of hydromor-
phone.
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was measured as described by French et al. (7), who defined 1 U of activity as the
amount of activity reducing 1 mmol of thionicotinamide NAD1 per min under
the conditions stated.
RESULTS
Cell-free biotransformations. The feasibility of cofactor cy-
cling by the STH was initially tested in a cell-free system using
purified enzyme preparations. The transformation of 20 mM
morphine in the presence of 0.2 mM concentrations of the
cofactors NADPH and NAD1 was evaluated in the presence
and absence of 1.25 U of STH per ml. The transforming en-
zymes MDH and MR were used at three different ratios of
activity by using equal amounts of MDH and MR (1.25 U/ml
each), excess MDH (6.25 U of MDH per ml and 1.25 U of MR
per ml), and excess MR (6.25 U of MR per ml and 1.25 U of
MDH per ml). The biotransformations were performed at pH
8.0 as a compromise between the pH optima of the three
enzymes (pH 9.6 for MDH [4], pH 7 to 8 for MR [8], and pH
7 to 8 for STH [not shown]). The enzymes were stable over the
course of the biotransformation, since no loss of activity was
observed when they were incubated in 50 mM Tris-HCl (pH
8.0) at 30°C for 9 h.
Samples were taken from the cell-free biotransformation at
regular intervals and analyzed for opiate content (Fig. 3). In
incubations with only MDH and MR, there was no conversion
of morphine (Fig. 3A, C, and E); however, when STH was
included in the incubation mixture, morphine was found to be
converted to hydromorphone and dihydromorphine (Fig. 3B,
D, and F).
Various amounts of hydromorphone and the unwanted side-
product dihydromorphine were observed depending on the
ratio of MDH and MR. With equal amounts of MDH and MR,
46% hydromorphone and 20% dihydromorphine were pro-
duced (Fig. 3B). An excess of MDH resulted in the low yields
of hydromorphone (21%) and high levels of dihydromorphine
(34%) (Fig. 3D). An excess of MR reduced the amount of
the unwanted side-product dihydromorphine (8.4%) and in-
creased hydromorphone yields (78%) (Fig. 3F).
Using an excess amount of MR (6.25 U/ml) compared to
that of MDH (1.25 U/ml), the effect of various amounts of
STH on the biotransformation was investigated (Fig. 4). This
analysis was performed using catalytic amounts of cofactor at
ratios likely to be found in the cell (2, 16, 26). The cofactor
concentrations used (2 mM NAD1, 0.15 mM NADH, 0.25 mM
NADP1, and 0.2 mM NADPH) accommodated the produc-
tion of only 0.15 mM (0.75% yield) hydromorphone without
cofactor cycling. With as little as 0.0625 U of STH per ml
compared to 6.25 U of MR per ml, conversion of morphine
was observed, but only low levels of product accumulated (17%
hydromorphone and 28% dihydromorphine) (Fig. 4B). By in-
creasing the amount of STH, yields of hydromorphone were
elevated while dihydromorphine levels decreased until an op-
timum was reached, after which no further improvement was
observed (Fig. 4D). Hydromorphone yields of up to 84% were
obtained, while as little as 4.5% dihydromorphine could be
seen to accumulate.
Construction of recombinant E. coli coexpressing MDH,
MR, and STH. In the original biotransformation system, the
genes morA and morB, which encode MDH and MR, respec-
tively, were coexpressed from the same pBluescript SK1-de-
rived plasmid, pMORAB5 (9). We cloned the P. fluorescens sth
gene on a compatible low-copy-number plasmid, ps 1EMBL
(21), which resulted in the plasmid pPFSTH4. The two plas-
mids pMORAB5 and pPFSTH4 are compatible in E. coli due
to their different origins of replication.
The original construct pMORAB5 expressed higher levels of
MDH than MR, and as indicated in the cell-free biotransfor-
mations, this was unfavorable. Furthermore, MDH became
inactivated by morphinone through the formation of a covalent
adduct with Cys80, and it was found that changing this residue
to a serine greatly enhanced the stability of MDH (25). A
mutation, K244M, leading to an approximately 10-fold-less-
active MDH was combined with the C80S mutation, to give
morA C80S z K244M (25). The mutant morA was subcloned
into the pBluescript SK1-based construct pMORB3, which
expressed morB (9), resulting in the plasmid pMORB3-
AC80S z K244M. The relative activities of MDH and MR
could in this way be altered without the need of modifying gene
expression, for instance, by the use of promoters of different
strengths or induction methods.
FIG. 3. Cell-free biotransformation of morphine at various ratios of MDH to
MR in the presence and absence of STH. The transformations were performed
without (A, C, and E) or with (B, D, and F) 1.25 U of STH per ml. MDH and
MR were used as the ratios 1:1 (1.25 U of each per ml) (A and B), 5:1 (6.25 U
of MDH per ml and 1.25 U of MR per ml (C and D), 1:5 (1.25 U of MDH per
ml and 6.25 U of MR per ml (E and F). The cofactors NADPH and NAD1 were
supplied at a concentration of 0.2 mM.
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Recombinant E. coli JM109 strains with and without pPFSTH4
were generated. The enzyme activities obtained from the dif-
ferent recombinant E. coli JM109 strains are shown in Table 1.
Whole-cell biotransformations. Whole-cell incubations with
20 mM morphine were performed with the recombinant strains
(Fig. 5). Biotransformations with the original construct E. coli
JM109/pMORAB5 demonstrated the rapid conversion of mor-
phine and the rapid but low-level accumulation of hydromor-
phone to a final yield of 37.1% 6 2.4% (Fig. 5A). High levels
(25.6% 6 0.5%) of the unwanted by-product dihydromorphine
were also found to accumulate. When STH was present in the
engineered strain E. coli JM109/pMORAB5/pPFSTH4, yields
of hydromorphone were found to be improved (51.7% 6 1.0%)
and less dihydromorphine accumulated (12.3% 6 2.7%) (Fig.
5B).
In the system which possessed lower levels of MDH than
of MR, E. coli JM109/pMORB3-AC80S z K244M, the yield
of hydromorphone increased to 58.7% 6 0.6% while the
level of dihydromorphine was reduced to 6.3% 6 0.1% (Fig.
5C). In comparison, the E. coli strain containing STH, JM109/
pMORB3-AC80S z K244M/pPFSTH4, appeared to convert
morphine more rapidly (Fig. 5D), and final yields were slightly
improved (67.1% 6 2.8% hydromorphone and 6.0% 6 0.6%
dihydromorphine).
Reuse of biocatalyst. The ability to reuse the same batch of
cells was investigated using E. coli JM109/pMORB3-AC80S z
K244M and E. coli JM109/pMORB3-AC80S z K244M/pPFSTH4.
A series of biotransformations was carried out using the same
batch of cells which were harvested and washed between incu-
bations. Enzyme assays of cells prior to each biotransformation
indicated that the levels of MDH, MR, and STH did not differ
significantly from the initial values determined at the point of
initial cell harvesting (data not shown). E. coli JM109/pMORB3-
AC80S z K244M cells were able to transform morphine effi-
ciently only once. The cells were then exhausted, resulting in a
very limited amount of hydromorphone being produced in a
second biotransformation (Fig. 6). In contrast, biotransforma-
tions with E. coli JM109/pMORB3-AC80S z K244M/pPFSTH4,
which contained STH, showed that these cells were able to
transform morphine efficiently over three cycles of incubations,
with only a small reduction in efficiency (Fig. 6).
An exhaustive attempt was made to measure the levels of
NAD and NADP in the cells, both before and after the bio-
transformations, using a variety of methods (11, 20, 24, 26);
however, it proved impossible to obtain reproducible data, pos-
sibly as the critical extraction procedure is difficult to perform
FIG. 4. Cell-free biotransformation of morphine in the presence of increas-
ing amounts of STH. The transformations were performed with 1.25 U of MDH
per ml and 6.25 U of MR per ml and various amounts of STH as follows: none
(A), 0.0625 U/ml (B), 0.125 U/ml (C), and 0.625 U/ml (D). With 1.25 and 6.25
U of STH per ml, the result was similar to that shown in panel D. The cofactors
used were 2 mM NAD1, 0.15 mM NADH, 0.25 mM NADP1, and 0.2 mM
NADPH.
FIG. 5. Whole-cell biotransformation of morphine with E. coli JM109/
pMORAB5 (A), E. coli JM109/pMORAB5/pPFSTH4 (B), E. coli JM109/
pMORB3-AC80S z K244M (C), and E. coli JM109/pMORB3-AC80S z K244M/
pPFSTH4 (D). Figures shown are the averages of duplicate measurements, and
error bars represent standard deviations.
TABLE 1. Enzyme activities obtained from expression
constructs in E. coli JM109a
Construct in
E. coli JM109
Sp act (U/mg) of:
MDH MR STH
pMORAB5 5.76 6 1.02 1.92 6 0.33 —
pMORAB5/pPFSTH4 4.19 6 0.07 1.60 6 0.08 0.58 6 0.01
pMORB3-AC80S z K244M 0.030 6 0.001 0.84 6 0.05 —
pMORB3-C80S z K244M/pPFSTH4 0.040 6 0.004 1.03 6 0.07 0.45 6 0.05
a Figures shown are the averages of triplicate measurements 6 the standard
deviations. Crude cell extracts were prepared as described in the text. Units of
enzyme activities are as defined in the text. —, no detectable activity.
5164 BOONSTRA ET AL. APPL. ENVIRON. MICROBIOL.
on resting cells or on cells that have undergone several manip-
ulations (such as centrifugation, washing, resuspension, etc.).
DISCUSSION
These experiments demonstrate that STH from P. fluore-
scens is able to regenerate the cofactors needed for the pro-
duction of hydromorphone in both cell-free and whole-cell
systems (Fig. 2). The cell-free biotransformation studies show
that STH is able to cycle the cofactors, thereby allowing the
efficient transformation of morphine in the presence of cata-
lytic amounts of cofactors to take place. The ratio of the three
enzymes is a critical parameter for optimum hydromorphone
yields. By keeping MR and STH activities high such that MDH
activity becomes rate limiting buildup of the unwanted side-
product dihydromorphine can be kept to a minimum and opi-
ate loss due to the spontaneous oxidation of the intermediate
morphinone can also be minimized since high levels of MR
rapidly convert morphinone to the more stable hydromor-
phone.
The inclusion of STH in the whole-cell biocatalyst clearly
improved the biotransformation of morphine and resulted in a
reuseable biocatalyst, implying that STH is able to recycle the
cofactors and maintain useful intracellular cofactor balances.
An apparent opiate loss (of up to 35%) can still be observed in
the biotransformations. Poor solubility of morphine combined
with the chemical instability of the intermediate morphinone,
which breaks down and can form polymeric products, are likely
causes of this apparent loss. The extended lifetime of the bio-
catalyst, however, raises the possibility of overcoming the prob-
lem of poor substrate solubility through the use of a continuous
substrate-cycling system.
The P. fluorescens STH is encoded by a single gene, enabling
straightforward regulated expression in recombinant systems.
As the reaction is not energy linked and is freely reversible, it
shows no predisposition towards a particular cofactor pool and
is likely to be of benefit to recombinant systems with different
cofactor requirements. While commonly used enzymatic meth-
ods for NAD and NADP regeneration are dependent on ad-
ditional supplies of substrate (10, 14, 17), the simultaneous
regeneration of both cofactors, one reduced and the other
oxidized, can be achieved by STH without the addition of any
other substrates.
E. coli has recently been found to possess a gene encoding an
STH; however, the activity was not detected in crude extracts
(3). As hydromorphone is found to accumulate at concentra-
tions up to 12 mM in whole-cell incubations without the re-
combinant STH present, a cell obviously contains significant
reserves of the cofactors or is to some extent able to regenerate
the cofactors due to other indigenous enzymes in the cell. Such
indigenous cofactor regeneration may possibly be envisaged,
for instance, for the two E. coli transhydrogenases. However,
the membrane-bound transhydrogenase couples the transfer of
reducing equivalents from NADH to NADP1 with proton
import and only in extreme conditions operates in the reverse
reaction (15), and the STH activity of E. coli is not detected.
These activities in the cell are, in any case, apparently not
sufficient for maintaining useful cofactor concentrations for the
efficient production of hydromorphone, and the introduction
of P. fluorescens STH facilitates cofactor cycling and thereby
improves the biotransformation.
Recently, Anderlund et al. (1) reported an attempt to use a
recombinant membrane-bound pyridine nucleotide transhy-
drogenase from E. coli to alter cofactor levels during anaerobic
fermentation of Saccharomyces cerevisiae. However, this en-
zyme was found to remain localized in the endoplasmic retic-
ulum, to have essentially no effect on NAD1 regeneration, and
to be unable to decrease glycerol formation. A cytoplasmic
transhydrogenase from Azotobacter vinelandii also did not pos-
itively affect the amount of glycerol produced by S. cerevisiae,
as the NAD1 pool became limiting (19). To the best of our
knowledge, this paper offers the first successful demonstration
of the use of a recombinant STH for cofactor regeneration.
Although problems with plasmid stability have not been en-
countered, it can be envisaged that integrating the P. fluore-
scens sth gene into the E. coli chromosome would further
enhance the suitability of the biocatalyst for commercial ap-
plications and also lead to a more general applicable cofactor
regeneration strain.
The results demonstrate the usefulness of STH as a tool in
biocatalysis and metabolic engineering programs where differ-
ent cofactor requirements limit product formation.
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